1. Cancer
  2. Cancer Metabolism and Metastasis

Cancer Metabolism and Metastasis

Metabolic abnormalities are a major feature of cancer, such as increased substance anabolic pathways and aerobic glycolysis. Cancer metabolism shows flexibility and plasticity, which are crucial for the survival and growth of cancer cells. Cancer metastasis is completed in five steps i.e. invasion, dissemination, circulating tumor cells, colonization, and secondary tumor formation. Recently, metabolic adaptation mechanism of cancer metastasis has been proposed to reveal the extensive relationship between cancer metabolism and cancer metastasis. Metastasizing cancer cells selectively and dynamically adapt their metabolism during the complex multistep cascade.

Many nutrients can promote metabolite plasticity during metastasis. For example, lactic acid and pyruvate are the nutrients that cells can directly absorb from the environment; many cancer cells take up glutamine, which contributes to non-essential amino acid as well as nucleotide synthesis through nitrogen or carbon metabolism. Inhibiting the function of key enzymes in metabolic pathways can in turn inhibit the proliferation of cancer cells. For example, lactate dehydrogenase A or B (LDH-A or -B) knockdown can inhibit breast cancer cell motility in vitro. Oncogenic signaling pathways, such as Myc, phosphoinositide 3-kinase (PI3K)/AKT pathway, MAPK/ERK pathway, LKB1/AMPK pathway and Hippo pathways, mediate metabolic gene expression and increase metabolic enzyme activities.

Cancer Metabolism and Metastasis Related Products (42547):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-13725AR
    Pirarubicin Hydrochloride (Standard) 95343-20-7
    Pirarubicin (Hydrochloride) (Standard) is the analytical standard of Pirarubicin (Hydrochloride). This product is intended for research and analytical applications. Pirarubicin Hydrochloride is an anthracycline antibiotics, acts as a topoisomerase II inhibitor, and is a widely used for treatment of various cancers, in particular, solid tumors.
    Pirarubicin Hydrochloride (Standard)
  • HY-N10351
    27-O-(tert-Butyldimethylsilyl)withaferin A 1392820-18-6
    27-O-(tert-Butyldimethylsilyl)withaferin A (compound 9a), a natural withanolide, is an apoptosis inducer. 27-O-(tert-Butyldimethylsilyl)withaferin A shows antiproliferative activity against HeLa, A-549 and MCF-7 human cancer cell lines, and against normal Vero cells.
    27-O-(tert-Butyldimethylsilyl)withaferin A
  • HY-D1468
    Phototherapeutic agent-1 2555045-67-3
    Phototherapeutic agent-1 is a multi-modal light diagnosis agent with aggregation-induced emission properties. have certain Phototherapeutic agent-1 has certain reactive oxygen species (ROS) generation capacity in illumination condition. Phototherapeutic agent-1 can effectively kill cancer cells and tumor tissue.
    Phototherapeutic agent-1
  • HY-107439
    Thalidomide-O-amido-C8-NH2 1950635-15-0
    Thalidomide-O-amido-C8-NH2 (Cereblon Ligand-Linker Conjugates 2), a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs.
    Thalidomide-O-amido-C8-NH2
  • HY-13562S
    Banoxantrone-d12 1562067-05-3
    Banoxantrone-d12 is the deuterium labeled banoxantrone. Banoxantrone is a novel bioreductive agent that can be reduced to a stable, DNA-affinic compound AQ4, which is a potent topoisomerase II inhibitor.
    Banoxantrone-d<sub>12</sub>
  • HY-13562AS
    Banoxantrone-d12 dihydrochloride 1562066-98-1
    Banoxantrone-d12 (dihydrochloride) is the deuterium labeled Banoxantrone dihydrochloride. Banoxantrone is a novel bioreductive agent that can be reduced to a stable, DNA-affinic compound AQ4, which is a potent topoisomerase II inhibitor.
    Banoxantrone-d<sub>12</sub> dihydrochloride
  • HY-100863
    BRCA1-IN-1 1622262-74-1
    BRCA1-IN-1 is a novel small-molecule-like BRCA1 inhibitor with IC50 and Ki of 0.53 μM and 0.71 μM, respecrively.
    BRCA1-IN-1
  • HY-103610
    4,4'-Dimethoxybenzil 1226-42-2 99.83%
    4,4'-Dimethoxybenzil is a human intestinal carboxyl esterase (hiCE) inhibitor with Ki of 70 nM.
    4,4'-Dimethoxybenzil
  • HY-U00304
    Aurora B inhibitor 1 937276-52-3
    Aurora B inhibitor 1 is an Aurora B (Aurora-1) inhibitor extracted from patent WO2007059299A1, compound 1-3, has a Ki value of <0.010 uM.
    Aurora B inhibitor 1
  • HY-15594
    Phen-DC3 942936-75-6
    Phen-DC3 is a G-quadruplex (G4) specific ligand which can inhibit FANCJ and DinG helicases with IC50s of 65±6 and 50±10 nM, respectively.
    Phen-DC3
  • HY-P0300
    Bak BH3 300349-67-1
    Bak BH3 is derived from the BH3 domain of Bak, can antagonize the function of Bcl-xL in cells.
    Bak BH3
  • HY-U00279
    Nitracrine 4533-39-5
    Nitracrine inhibits RNA synthesis and covalently, reversibly binds to DNA but also forms covalent adducts with DNA in vivo. Nitracrine, a 1-nitroacridine derivative, is a potent hypoxia-selective agent in vitro and antitumor agent. Nitracrine has cytotoxicity towards most cells.
    Nitracrine
  • HY-U00358
    Compound 2 872313-42-3
    Compound 2 is an active compound used for the research of metabolic bone diseases.
    Compound 2
  • HY-N0624
    Complanatoside A 146501-37-3
    Complanatoside A is a flavonol glycoside isolated from Astragalus complanatus, and currently it is used as a quality control index for A. complanatus in the 2010 edition of the Chinese Pharmacopoeia.
    Complanatoside A
  • HY-P0301
    SLLK, Control Peptide for TSP1 Inhibitor 2918768-29-1
    SLLK, Control Peptide for TSP1 Inhibitor is a control peptide for LSKL (leucine-serine-lysine-leucine).
    SLLK, Control Peptide for TSP1 Inhibitor
  • HY-P0307
    Antennapedia Peptide 188842-14-0 98.35%
    Antennapedia Peptide (Penetratin peptide) is a 16 amino acid peptide, originally derived from the 60 amino acid long homeodomain of the Drosophila transcription factor Antennapedia and is a member of the family of cell-penetrating peptides.
    Antennapedia Peptide
  • HY-U00324
    p38 MAPK-IN-2 635725-16-5
    p38 MAPK-IN-2 is an inhibitor of p38 kinase.
    p38 MAPK-IN-2
  • HY-U00247
    MCI826 140646-80-6
    MCI826 is a P-glycoprotein (P-gp) antagonist.
    MCI826
  • HY-U00414
    Antitumor agent-4 115767-64-1
    Antitumor agent-4, a butenylphenyl phosphate derivative, is a agent for mammary cancer and anovulatory sterility.
    Antitumor agent-4
  • HY-U00321
    A2B receptor antagonist 1 531506-36-2
    A2B receptor antagonist 1 is a potent A2B adenosine receptor antagonist extracted from patent WO 2009157938 A1 EXAMPLE 9B.
    A2B receptor antagonist 1